Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GALR3 | O60755 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.73 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.73 |
| ▸ | PDE4A | P27815 | 3/20 | 0.73 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.73 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.73 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | PDE5A | O76074 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | PDE2A | O00408 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8210361 | 0.86 | KDM4E (0.75) | KDM4EHPGDALDH1A1GAAGALR3 | |
| SCHEMBL5470727 | 0.84 | HPGD (0.73) | KDM4EHPGDALDH1A1GAAGALR3 | |
| Milrinone SCHEMBL9247989 | 0.84 | PDE3A (1.00) | KDM4EHPGDALDH1A1GAAGALR3 | |
| SCHEMBL9587750 | 0.84 | KDM4E (0.73) | KDM4EHPGDALDH1A1GAAGALR3 | |
| SCHEMBL10891425 | 0.84 | KDM4E (0.73) | KDM4EHPGDALDH1A1GAAGALR3 | |
| Milrinone SCHEMBL9309054 | 0.84 | PDE3A (1.00) | KDM4EHPGDALDH1A1GAAGALR3 | |
| Milrinone SCHEMBL36947 | 0.84 | PDE3A (1.00) | KDM4EHPGDALDH1A1GAAGALR3 | |
| SCHEMBL7407595 | 0.84 | KDM4E (0.73) | KDM4EHPGDALDH1A1GAAGALR3 | |
| Milrinone SCHEMBL9301167 | 0.84 | PDE3A (1.00) | KDM4EHPGDALDH1A1GAAGALR3 | |
| SCHEMBL7321021 | 0.84 | KDM4E (0.72) | KDM4EHPGDALDH1A1GAAGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | claimed |
| JP-2006513222-A | — | — | 2006-04-20 | — | — | JP | claimed |
| EP-1575923-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST &bgr;-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | Artesian Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058726-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | claimed |
| US-5153209-A | Cardiotonic agents | GLAXO INC. (US) | 1992-10-06 | — | — | US | claimed |
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | ARTESIAN THERAPECUTICS, INC (US) | 2007-05-24 | — | — | US | disclosed |
| EP-1575923-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST &bgr;-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | Artesian Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058726-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-0636142-B1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | disclosed |
| US-5721222-A | Heterocyclic ketones | ZENECA LIMITED (GB) | 1998-02-24 | — | — | US | disclosed |
| EP-0630382-B1 | LACTAM DIPEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LTD (GB) | 1997-02-26 | — | — | EP | disclosed |
| EP-0509769-B1 | Heterocyclic amides having HLE inhibiting activity | ZENECA LTD (GB) | 1996-09-11 | — | — | EP | disclosed |
| WO-1993021209-A1 | LACTAM PEPTIDES HAVING HLE INHIBITING ACTIVITY | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| US-5010086-A | Enzyme inhibitor for treating congestive heart failure or hypertension in mammals | STERLING DRUG INC. (US) | 1991-04-23 | — | — | US | disclosed |
| US-4963561-A | Phosphodiesterase inhibitors | STERLING DRUG INC. (US) | 1990-10-16 | — | — | US | disclosed |
| US-4508722-A | 1-Benzoyl-3-(arylpyridyl)urea compounds | ELI LILLY AND COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| US-4405552-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| EP-0060071-A1 | Improvements in or relating to 1-benzoyl-3-(arylpyridyl)urea compounds | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
| WO-1981002575-A1 | DERIVATIVES OF 2(1H)-PYRIDINONE,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SANDOZ AG (CH) | 1981-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117978-A1 | Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase | PDE3A, PDE4A, PDE3B | KDM4E 3236/4885HPGD 1051/4885ALDH1A1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.